<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease - Chande, N - 2016 | Cochrane Library</title> <meta content="Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease - Chande, N - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000545.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease - Chande, N - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000545.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000545.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease" name="citation_title"/> <meta content="Nilesh Chande" name="citation_author"/> <meta content="London Health Sciences Centre ‐ Victoria Hospital" name="citation_author_institution"/> <meta content="nilesh.chande@lhsc.on.ca" name="citation_author_email"/> <meta content="Cassandra M Townsend" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="Claire E Parker" name="citation_author"/> <meta content="Robarts Clinical Trials" name="citation_author_institution"/> <meta content="John K MacDonald" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD000545.pub5" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/10/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000545.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000545.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000545.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antimetabolites [adverse effects, *therapeutic use]; Azathioprine [adverse effects, *therapeutic use]; Crohn Disease [*drug therapy]; Glucocorticoids [administration &amp; dosage]; Immunosuppressive Agents [adverse effects, *therapeutic use]; Induction Chemotherapy [*methods, statistics &amp; numerical data]; Infliximab [therapeutic use]; Mercaptopurine [adverse effects, *therapeutic use]; Mesalamine [therapeutic use]; Prednisone [administration &amp; dosage]; Randomized Controlled Trials as Topic; Sulfasalazine [therapeutic use]; Withholding Treatment" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000545.pub5&amp;doi=10.1002/14651858.CD000545.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="sogqpCtr";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000545\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000545\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","zh_HANS","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000545.pub5",title:"Azathioprine or 6\\u2010mercaptopurine for induction of remission in Crohn\u0027s disease",firstPublishedDate:"Oct 26, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000545.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000545.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000545.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000545.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000545.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000545.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000545.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000545.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000545.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000545.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3117 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000545.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-sec-0034"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-sec-0010"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-sec-0011"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-sec-0024"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-sec-0033"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/appendices#CD000545-sec-0039"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/table_n/CD000545StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/table_n/CD000545StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/information#CD000545-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Nilesh Chande</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/information#CD000545-cr-0003">Cassandra M Townsend</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/information#CD000545-cr-0004">Claire E Parker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000545.pub5/information#CD000545-cr-0005">John K MacDonald</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/information/en#CD000545-sec-0048">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 October 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000545.pub5">https://doi.org/10.1002/14651858.CD000545.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000545-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000545-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000545-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000545-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000545-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000545-abs-0001" lang="en"> <section id="CD000545-sec-0001"> <h3 class="title" id="CD000545-sec-0001">Background</h3> <p>The results from controlled clinical trials investigating the efficacy of azathioprine and 6‐mercaptopurine for the treatment of active Crohn's disease have been conflicting and controversial. An updated meta‐analysis was performed to assess the effectiveness of these drugs for the induction of remission in active Crohn's disease. </p> </section> <section id="CD000545-sec-0002"> <h3 class="title" id="CD000545-sec-0002">Objectives</h3> <p>The primary objective was to determine the efficacy and safety of azathioprine and 6‐mercaptopurine for induction of remission in active Crohn's disease. </p> </section> <section id="CD000545-sec-0003"> <h3 class="title" id="CD000545-sec-0003">Search methods</h3> <p>We searched MEDLINE, EMBASE and the Cochrane Library from inception to 30 October 2015. Review articles and conference proceedings were also searched to identify additional studies. </p> </section> <section id="CD000545-sec-0004"> <h3 class="title" id="CD000545-sec-0004">Selection criteria</h3> <p>Randomized controlled trials (RCTs) of oral azathioprine or 6‐mercaptopurine compared to placebo or active therapy involving adult patients with active Crohn's disease were selected for inclusion. </p> </section> <section id="CD000545-sec-0005"> <h3 class="title" id="CD000545-sec-0005">Data collection and analysis</h3> <p>Data were extracted by two independent observers based on the intention‐to‐treat principle. Outcomes of interest included: clinical remission, clinical improvement, fistula improvement or healing, steroid sparing, adverse events, withdrawals due to adverse events and serious adverse events. We calculated the pooled relative risk (RR) and 95% confidence intervals (95% CI) for each outcome. The methodological quality of included studies was evaluated using the Cochrane risk of bias tool. The overall quality of the evidence supporting each outcome was assessed using the GRADE criteria. </p> </section> <section id="CD000545-sec-0006"> <h3 class="title" id="CD000545-sec-0006">Main results</h3> <p>Thirteen RCTs (n = 1211 patients) of azathioprine and 6‐mercaptopurine therapy in adult patients were identified: nine included placebo comparators and six included active comparators. The majority of included studies were rated as low risk of bias. There was possibly a modest difference in clinical remission rates between azathioprine or 6‐mercaptopurine and placebo. Forty‐eight per cent (95/197) of patients receiving antimetabolites achieved remission compared to 37% (68/183) of placebo patients (5 studies, 380 patients; RR 1.23, 95% CI 0.97 to 1.55; moderate quality evidence). There was possibly a modest difference in clinical improvement rates between azathioprine or 6‐mercaptopurine and placebo. Forty‐eight per cent (107/225) of patients receiving antimetabolites achieved clinical improvement or remission compared to 36% (75/209) of placebo patients (8 studies, 434 patients; RR 1.26, 95% CI 0.98 to 1.62; moderate quality evidence). There was possibly a modest difference in steroid sparing (defined as prednisone dose &lt; 10 mg/day while maintaining remission) between azathioprine and placebo. Sixty‐four per cent (47/73) of azathioprine patients were able to reduce their prednisone dose to &lt; 10 mg/day compared to 46% (32/70) of placebo patients (RR 1.34, 95% CI 1.02 to 1.77; moderate quality evidence). GRADE analyses rated the overall quality of the evidence for the outcomes clinical remission, clinical improvement and steroid sparing as moderate due to sparse data. </p> <p>There was possibly a modest difference in withdrawals due to adverse events or serious adverse events between antimetabolites and placebo. Ten percent of patients in the antimetabolite group withdrew due to adverse events compared to 5% of placebo patients (8 studies, 510 patients; RR 1.70, 95% CI 0.94 to 3.08; moderate quality evidence). Serious adverse events were reported in 14% of patients receiving azathioprine compared to 4% of placebo patients (2 studies, 216 patients; RR 2.57, 95% CI 0.92 to 7.13; low quality evidence). Common adverse events reported in the placebo controlled studies included: allergic reactions. leukopenia, pancreatitis and nausea. Azathioprine was probably inferior to infliximab for induction of steroid‐free clinical remission. Thirty per cent (51/170) of azathioprine patients achieved steroid‐free remission compared to 44% (75/169) of infliximab patients (1 study, 339 patients; RR 0.68, 95% CI 0.51 to 0.90; moderate quality evidence). The combination of azathioprine and infliximab was probably superior to infliximab alone for induction of steroid‐free clinical remission. Sixty per cent (116/194) of patients in the combined azathioprine and infliximab group achieved steroid‐free remission compared to 48% (91/189) of infliximab patients (2 studies, 383 patients; RR 1.23, 95% CI 1.02 to 1.47; moderate quality evidence). Azathioprine or 6‐mercaptopurine therapy was found to be possibly superior at inducing steroid free clinical remission compared to methotrexate (RR 1.13, 95% CI 0.85 to 1.49; low quality evidence) and the evidence was very uncertain as regards the comparison with 5‐aminosalicylate or sulfasalazine (RR 1.24, 95% CI 0.80 to 1.91; very low quality evidence). The estimates for withdrawals due to adverse events between the various drugs were as follows: azathioprine or 6‐mercaptopurine versus methotrexate:RR 0.78, 95% CI 0.23 to 2.71; very low quality evidence; azathioprine or 6‐mercaptopurine versus 5‐aminosalicylate or sulfasalazine: RR 0.98, 95% CI 0.38 to 2.54; low quality evidence; azathioprine versus infliximab: RR 1.47, 95% CI 0.96 to 2.23; moderate quality evidence and the combination of azathioprine and infliximab versus infliximab: RR 1.16, 95% CI 0.75 to 1.80; moderate quality evidence. Common adverse events in the active comparator trials included nausea, abdominal pain, pyrexia and headache. </p> </section> <section id="CD000545-sec-0007"> <h3 class="title" id="CD000545-sec-0007">Authors' conclusions</h3> <p>Azathioprine and 6‐mercaptopurine possibly offer a modest advantage over placebo for induction of remission or clinical improvement in active Crohn's disease. Antimetabolite therapy possibly allows patients to reduce steroid consumption. Adverse events are possibly more common in patients receiving antimetabolites compared to those receiving placebo. Azathioprine therapy is probably inferior to infliximab for induction of steroid‐free remission. However, the combination of azathioprine and infliximab is probably superior to infliximab alone for induction of steroid‐free remission. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000545-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000545-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000545-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000545-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000545-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000545-abs-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000545-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000545-abs-0002" lang="en"> <h3>Azathioprine or 6‐mercaptopurine for the treatment of active Crohn's disease</h3> <p>Azathioprine and 6‐mercaptopurine are immunosuppressive drugs that are thought to reduce inflammation by blocking the immune system. This review includes 13 randomized trials with a total of 1211 participants. Azathioprine and 6‐mercaptopurine were found to be possibly more effective than placebo (fake medicine) for inducing remission in Crohn's disease. There is evidence to suggest that the combination of azathioprine and infliximab is superior to infliximab used as a single drug for induction of steroid‐free remission in active Crohn's disease. Tumor necrosis factor (TNF) alpha blocking drugs like infliximab may provide an alternative treatment for patients who do not respond to corticosteroid or immunosuppressive drug treatment. Azathioprine and 6‐mercaptopurine may reduce the need for steroid treatment and their use may therefore lead to a lower incidence of steroid related side effects. However, these drugs are slow acting and are associated with some rare, but serious side effects. In some patients they suppress formation of blood cells that fight off infection and allow blood to clot and they occasionally cause inflammation of the pancreas. These drugs have also been associated with an increased risk of lymphoma. For these reasons careful consideration needs to be given to the use of these drugs in patients with active Crohn's disease. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000545-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000545-sec-0034"></div> <h3 class="title" id="CD000545-sec-0035">Implications for practice</h3> <section id="CD000545-sec-0035"> <p>Azathioprine and 6‐mercaptopurine possibly offer a modest advantage over placebo for induction of remission or clinical improvement in active Crohn's disease. Antimetabolite therapy possibly allows patients to reduce steroid consumption. There is evidence to suggest that the combination of azathioprine and infliximab is probably superior to infliximab monotherapy for induction of steroid‐free remission in active Crohn's disease. Adverse events are possibly more common in patients receiving antimetabolites compared to those receiving placebo. </p> </section> <h3 class="title" id="CD000545-sec-0036">Implications for research</h3> <section id="CD000545-sec-0036"> <p>All of the studies reported in this analysis used clinical improvement or remission as the primary outcome. It would be of interest to know whether azathioprine or 6‐mercaptopurine can induce mucosal healing. Preliminary uncontrolled observations have suggested that azathioprine does result in endoscopic healing of active Crohn's disease (<a href="./references#CD000545-bbs2-0048" title="D'HaensG , GeboesK , PonetteE , PenninckxF , RutgeertsP . Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology1997;112(5):1475‐81. ">D'Haens 1997</a>; <a href="./references#CD000545-bbs2-0079" title="SandbornWJ , VanOsEC , ZinsBJ , TremaineWJ , MaysDC , LipskyJJ . An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology1995;109(6):1808‐17. ">Sandborn 1995</a>;). Future studies should assess time to steroid‐free remission as an outcome. The available data on fistulae closure in patients with Crohn's disease treated with azathioprine or 6‐mercaptopurine is not adequate to make definite conclusions regarding efficacy. A randomized, double‐blind, placebo‐controlled trial of azathioprine therapy in patients with active fistulizing Crohn's disease would be of interest. More high quality trials comparing azathioprine or 6‐mercaptopurine with 5‐aminosalicyclates or methotrexate are required to determine the true comparative efficacy and safety of these interventions. Further research is required to confirm the superiority of combination of azathioprine and infliximab to infliximab monotherapy. Future research should also assess the efficacy and safety of the use of azathioprine with other biologics. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000545-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000545-sec-0008"></div> <div class="table" id="CD000545-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus placebo for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Azathioprine (AZA) or 6‐mercaptopurine (6‐MP) versus placebo for induction of remission in Crohn's disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with active Crohn's disease<br/> <b>Settings:</b> Outpatients<br/> <b>Intervention:</b> Azathioprine or 6‐mercaptopurine versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>AZA or 6‐MP versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>372 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b><br/> (361 to 577) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> <br/> (0.97 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>380<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical remission or improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>359 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>452 per 1000</b><br/> (352 to 582) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.26</b> <br/> (0.98 to 1.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>434<br/> (8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fistula improvement or healing</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>286 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>572 per 1000</b><br/> (192 to 1696) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.00</b> <br/> (0.67 to 5.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Steroid sparing effect</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>457 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>612 per 1000</b><br/> (466 to 809) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.34</b> <br/> (1.02 to 1.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>53 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>90 per 1000</b><br/> (50 to 163) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.70</b> </p> <p>(0.94 to 3.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>510<br/> (8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>38 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>98 per 1000</b> </p> <p>(35 to 271)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.57</b> </p> <p>(0.92 to 7.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>216 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of meta‐analysis, based on included trials<br/> <sup>2</sup> Sparse data (163 events)<br/> <sup>3</sup> Sparse data (182 events)<br/> <sup>4</sup> Sparse data (8 events) and very wide confidence intervals<br/> <sup>5</sup> Sparse data (79 events)<br/> <sup>6</sup> Sparse data (41 events) </p> <p><sup>7</sup> Sparse data (19 events) and very wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000545-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azathioprine versus infliximab for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Azathioprine (AZA) versus infliximab (IFX) for induction of remission in Crohn's disease</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with active Crohn's disease<br/> <b>Settings:</b> Outpatients<br/> <b>Intervention:</b> Azathioprine versus infliximab </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>AZA versus IFX</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>479 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b><br/> (244 to 417) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.66</b> <br/> (0.51 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>339<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical remission off steroids</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>444 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>302 per 1000</b><br/> (226 to 400) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.68</b> <br/> (0.51 to 0.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>339<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mucosal healing</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>283 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>156 per 1000</b><br/> (93 to 266) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.55</b> <br/> (0.33 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>214<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>890 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>899 per 1000</b><br/> (828 to 961) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b> <br/> (0.93 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>178 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>262 per 1000</b><br/> (171 to 397) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.47</b> <br/> (0.96 to 2.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>239 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>268 per 1000</b><br/> (184 to 387) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.12</b> <br/> (0.77 to 1.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of the study<br/> <sup>2</sup> Sparse data (135 events)<br/> <sup>3</sup> Sparse data (126 events)<br/> <sup>4</sup> Sparse data (46 events)<br/> <sup>5</sup> Sparse data (289 events)<br/> <sup>6</sup> Sparse data (71 events)<br/> <sup>7</sup> Sparse data (82 events) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000545-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azathioprine + infliximab versus infliximab for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Azathioprine (AZA) + infliximab (IFX) versus infliximab for induction of remission in Crohn's disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with active Crohn's disease<br/> <b>Settings:</b> Outpatients<br/> <b>Intervention:</b> Azathioprine + infliximab versus infliximab </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>AZA + IFX versus IFX</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>479 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>603 per 1000</b><br/> (493 to 738) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> <br/> (1.03 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical remission off steroids</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>482 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>593 per 1000</b><br/> (492 to 708) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.23</b> <br/> (1.02 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mucosal healing</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>283 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>424 per 1000</b><br/> (289 to 620) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.50</b> <br/> (1.02 to 2.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>890 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>899 per 1000</b><br/> (837 to 970) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b> <br/> (0.94 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>178 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>206 per 1000</b><br/> (134 to 320) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.16</b> <br/> (0.75 to 1.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>239 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>151 per 1000</b><br/> (98 to 234) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.63</b> <br/> (0.41 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of the study<br/> <sup>2</sup> Sparse data (183 events)<br/> <sup>3</sup> Sparse data (207 events)<br/> <sup>4</sup> Sparse data (75 events)<br/> <sup>5</sup> Sparse data (306 events)<br/> <sup>6</sup> Sparse data (66 events)<br/> <sup>7</sup> Sparse data (66 events) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000545-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus methotrexate for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Azathioprine (AZA) or 6‐mercaptopurine (6‐MP) versus methotrexate (MTX) for induction of remission in Crohn's disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with active Crohn's disease<br/> <b>Settings:</b> Outpatients<br/> <b>Intervention:</b> Azathioprine or 6‐mercaptopurine versus methotrexate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>AZA or 6‐MP versus MTX</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>565 per 1000</b><br/> (425 to 1210) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> <br/> (0.85 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>452 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>190 per 1000</b><br/> (95 to 371) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.42</b> <br/> (0.21 to 0.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>5,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>119 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>93 per 1000</b><br/> (27 to 322) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.78</b> <br/> (0.23 to 2.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very</b> l<b>ow</b><sup>7,8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Definition of clinical remission includes withdrawal from steroids.<br/> <sup>2</sup> Control group risk estimates come from control arm of meta‐analysis, based on included trials<br/> <sup>3</sup> Sparse data (75 events)<br/> <sup>4</sup> Two of the studies in the pooled analysis were rated as having a high risk of bias due to single‐blind and open label designs<br/> <sup>5</sup> Sparse data (27 events)<br/> <sup>6</sup> The two studies in the pooled analysis were rated as having a high risk of bias due to single‐blind and open label designs<br/> <sup>7</sup> Sparse data (9 events) and very wide confidence intervals<br/> <sup>8</sup> The two studies in the pooled analysis were rated as having a high risk of bias due to single‐blind and open label designs </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000545-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus 5‐ASA or Sulfasalzine for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>6‐mercaptopurine (6‐MP) versus 5‐ASA for induction of remission in Crohn's disease</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with active Crohn's disease<br/> <b>Settings:</b> Outpatients<br/> <b>Intervention:</b> Azathioprine or 6‐mercaptopurine versus 5‐ASA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6‐MP versus 5‐ASA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>358 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>444 per 1000</b><br/> (286 to 684) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.24</b> (0.80 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>99 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>97 per 1000</b> (38 to 251) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.98</b> (0.38 to 2.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>3,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of study<br/> <sup>2</sup> Sparse data (65 events)<br/> <sup>3</sup><a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a> was rated as having a high risk of bias due to open label design </p> <p><sup>4</sup> Unexplained heterogeneity </p> <p><sup>5</sup> Sparse data (15 events) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000545-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000545-sec-0009"></div> <p>6‐Mercaptopurine (6‐MP) (predominantly used as a chemotherapeutic agent) and its prodrug azathioprine (AZA) (an immune modifier agent) are purine analogues that competitively interfere with nucleic acid metabolism (<a href="./references#CD000545-bbs2-0067" title="LennardL . The clinical pharmacology of 6‐mercaptopurine. European Journal of Clinical Pharmacology1992;43(4):329‐39. ">Lennard 1992</a>; <a href="./references#CD000545-bbs2-0078" title="SahasranamanS , HowardD , RoyS . Clinical pharmacology and pharmacogenetics of thiopurines. European Journal of Clinical Pharmacology2008;64:753‐67. ">Sahasranaman 2008</a>). Consequently, both drugs reduce cell proliferation and have immune modulating properties. A deficiency of thiopurine methyltransferase (TPMT) enzyme appears to account for some dose‐ and metabolism‐dependent toxicities such as leukopenia (and possible subsequent infection), thrombocytopenia, and malignancy (<a href="./references#CD000545-bbs2-0065" title="LennardL , ReesCA , LilleymanJS , MaddocksJL . Childhood leukaemia: a relationship between intracellular 6‐mercaptopurine metabolites and neutropenia. British Journal of Clinical Pharmacology1983;16(4):359‐63. ">Lennard 1983</a>; <a href="./references#CD000545-bbs2-0066" title="LennardL , VanLoonJA , WeinshilboumRM . Pharmacogenitics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clinical Pharmacology and Therapeutics1989;46(2):149‐54. ">Lennard 1989</a>; <a href="./references#CD000545-bbs2-0086" title="WeinshilboumRN , SladekSL . Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. American Journal of Human Genetics1980;32(5):651‐62. ">Weinshilboum 1980</a>). Other toxicities such as rash, fever, arthralgias, pancreatitis, hepatitis, nausea, non‐pancreatic abdominal pain and diarrhea appear to be hypersensitivity reactions (<a href="./references#CD000545-bbs2-0080" title="SandbornWJ . A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6‐mercaptopurine, cyclosporine, and methotrexate. American Journal of Gastroenterology1996;91(3):423‐33. ">Sandborn 1996</a>). </p> <p>Azathioprine and 6‐mercaptopurine have both been used to treat patients with active, steroid‐refractory, and steroid‐dependent Crohn's disease, and patients with fistulizing Crohn's disease. Uncontrolled trials suggested efficacy for azathioprine (<a href="./references#CD000545-bbs2-0038" title="Avery‐JonesF , Lennard‐JonesJE , HintonJM , ReevesWG . Dangers of immuno‐suppressive drugs in ulcerative colitis (letter). British Medical Journal1966;1:1418. ">Avery‐Jones 1966</a>; <a href="./references#CD000545-bbs2-0040" title="BrookeBN , HoffmannDC , SwarbrickET . Azathioprine for Crohn's disease. Lancet1969;2(7621):612‐4. ">Brooke 1969</a>; <a href="./references#CD000545-bbs2-0041" title="BrookeBN , JavettSL , DavisonOW . Further experience with azathioprine for Crohn's disease. Lancet1970;2(7682):1050‐3. ">Brooke 1970</a>; <a href="./references#CD000545-bbs2-0042" title="BrookeBN , CaveDR , KingDW . Place of azathioprine for Crohn's disease. Lancet1976;1(7968):1041‐2. ">Brooke 1976</a>; <a href="./references#CD000545-bbs2-0043" title="BrownCH , AchkarE . Azathioprine therapy for inflammatory bowel disease. A preliminary report. American Journal of Gastroenterology1970;54(4):363‐77. ">Brown 1970</a>; <a href="./references#CD000545-bbs2-0044" title="ColonnaT , KorelitzBI . The role of leukopenia in the 6‐mercaptopurine‐induced remission of refractory Crohn's disease. American Journal of Gastroenterology1994;89(3):362‐6. ">Colonna 1994</a>; <a href="./references#CD000545-bbs2-0047" title="D'HaensG , CallensJ , HieleM , PeetersM , RutgeertsP . Reduction of neutrophil and not lymphocyte count is associated with favourable response to azathioprine therapy in refractory Crohn's disease. Gastroenterology1995;108:A809. ">D'Haens 1995</a>; <a href="./references#CD000545-bbs2-0048" title="D'HaensG , GeboesK , PonetteE , PenninckxF , RutgeertsP . Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology1997;112(5):1475‐81. ">D'Haens 1997</a><a href="./references#CD000545-bbs2-0049" title="DruckerWR , JeejeebhoyKN . Azathioprine: an adjunct to surgical therapy of granulomatous enteritis. Annals of Surgery1970;172(4):618‐26. ">Drucker 1970</a>; <a href="./references#CD000545-bbs2-0050" title="FausaO , GjoneE . Azathioprine (Imurel) therapy in Crohn's disease. Acta Medica Scandinavica1971;190(3):211‐2. ">Fausa 1971</a>; <a href="./references#CD000545-bbs2-0058" title="JavettSL , HoffmannVJ . Azathioprine in acute Crohn's disease. South African Medical Journal1972;46(38):1369. ">Javett 1972</a>; <a href="./references#CD000545-bbs2-0059" title="KesslerBH , PetteiMJ , WeinsteinT , GoldDM , LevineJJ . 6‐Mercaptopurine (6‐MP) in pediatric Crohn's disease: high dose versus conventional dose. Gastroenterology1995;108:A848. ">Kessler 1995</a><a href="./references#CD000545-bbs2-0062" title="KorelitzBI , PresentDH . Favorable effect of 6‐mercaptopurine on fistulae of Crohn's disease. Digestive Diseases and Sciences1985;30(1):58‐64. ">Korelitz 1985</a>; <a href="./references#CD000545-bbs2-0063" title="KorelitzBI , AdlerDJ , MendelsohnRA , SacknoffAL . Long‐term experience with 6‐mercaptopurine in the treatment of Crohn's disease. American Journal of Gastroenterology1993;88(8):1198‐205. ">Korelitz 1993</a>; <a href="./references#CD000545-bbs2-0064" title="LémannM , BonhommeP , BitounA , MessingB , ModiglianiR , RambaudJC . Traitment de la maladie de Crohn par l'azathioprine ou la 6‐mercaptopurine. Gastroentérologie Clinique et Biologique1990;14(6‐7):548‐54. ">Lemann 1990</a>; <a href="./references#CD000545-bbs2-0068" title="Lennard‐JonesJE , WilliamsCB . Azathioprine in the treatment of Crohn's disease. Proceedings of the Royal Society of Medicine1972;65:291‐3. ">Lennard‐Jones 1972</a>; <a href="./references#CD000545-bbs2-0070" title="MarkowitzJ , RosaJ , GrancherK , AigesH , DaumF . Long‐term 6‐mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology1990;99(5):1347‐51. ">Markowitz 1990</a>; <a href="./references#CD000545-bbs2-0071" title="NymanM , HanssonI , ErikssonS . Long‐term immunosuppressive treatment in Crohn's disease. Scandinavian Journal of Gastroenterology1985;20(10):1197‐203. ">Nyman 1985</a>; <a href="./references#CD000545-bbs2-0072" title="O'BrienJJ , BaylessTM , BaylessJA . Use of azathioprine or 6‐mercaptopurine in the treatment of Crohn's disease. Gastroenterology1991;101(1):39‐46. ">O'Brien 1991</a>; <a href="./references#CD000545-bbs2-0074" title="PattersonJF , NortonRA , SchwartzRS . Azathioprine treatment of ulcerative colitis, granulomatous colitis and regional enteritis. American Journal of Digestive Diseases1971;16(2):327‐32. ">Patterson 1971</a>; <a href="./references#CD000545-bbs2-0073" title="PappJP , WatsonDW , BullFE . Azathioprine treatment in Crohn's disease. American Journal of Gastroenterology1974;61(2):136‐42. ">Papp 1974</a>; <a href="./references#CD000545-bbs2-0075" title="PerraultJ , GresethJL , TremaineWJ . 6‐Mercaptopurine therapy in selected cases of corticosteroid‐dependent Crohn's disease. Mayo Clinic Proceedings1991;66(5):480‐4. ">Perrault 1991</a>; <a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a>; <a href="./references#CD000545-bbs2-0083" title="ShahMD , BermanWF . Use of azathioprine in nine children with Crohn's disease. Virginia Medical Quarterly1991;118(3):169‐70. ">Shah 1991</a>; <a href="./references#CD000545-bbs2-0084" title="VerhaveM , WinterHS , GrandRJ . Azathioprine in the treatment of children with inflammatory bowel disease. Journal of Pediatrics1990;117(5):809‐14. ">Verhave 1990</a>; <a href="./references#CD000545-bbs2-0085" title="WallenstenS , PerssonS . Azathioprine therapy for Crohn's disease. Acta Chirurgica Scandinavica1972;138(5):521‐6. ">Wallensten 1972</a>). Placebo controlled clinical trials have been performed in order to determine whether the results of these uncontrolled studies are valid (<a href="./references#CD000545-bbs2-0002" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. ">Candy 1995</a>; <a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>; <a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>; <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>; <a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a>; <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>; <a href="./references#CD000545-bbs2-0013" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7731):944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). The results from these controlled trials were conflicting and controversies regarding efficacy developed (<a href="./references#CD000545-bbs2-0061" title="KorelitzBI , PresentDH . Shortcomings of the National Crohn's Disease Study: the exclusion of azathioprine without adequate trial. Gastroenterology1981;80(1):193‐6. ">Korelitz 1981</a>; <a href="./references#CD000545-bbs2-0069" title="Lennard‐JonesJE . Azathioprine and 6‐mercaptopurine have a role in the treatment of Crohn's disease. Digestive Diseases and Sciences1981;26(4):364‐8. ">Lennard‐Jones 1981</a>). Much of the controversy centered on design flaws in some of the studies, which failed to take into account the prolonged time to onset of drug action (3 to 4 months minimum). Careful analysis of the controlled data, paying attention to duration of therapy, concomitant medications, and drug dosage, may reveal logical explanations for conflicting data and allow more valid conclusions to be reached regarding efficacy. There have also been studies comparing AZA or 6‐MP to other active treatments or in combination with these treatments (<a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a>; <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>). This systematic review is an update of a previously published Cochrane review (<a href="./references#CD000545-bbs2-0087" title="ChandeN , TsoulisDJ , MacDonaldJK . Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD000545.pub4] ">Chande 2013</a>). </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000545-sec-0010" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000545-sec-0010"></div> <p>The primary objective was to assess the efficacy and safety of azathioprine and 6‐mercaptopurine used for induction of remission in active Crohn's disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000545-sec-0011" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000545-sec-0011"></div> <section id="CD000545-sec-0012"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000545-sec-0013"> <h4 class="title">Types of studies</h4> <p>Randomized placebo‐controlled or active comparator trials were considered for inclusion.</p> </section> <section id="CD000545-sec-0014"> <h4 class="title">Types of participants</h4> <p>Adult patients with Crohn's disease defined by conventional clinical, radiographic, and endoscopic criteria which was categorized as acute (active) inflammatory disease (CDAI &gt; 150 points or Harvey‐Bradshaw Index score &gt; 7 points or presence of moderate to severe symptoms at the time of entry into the trial). </p> </section> <section id="CD000545-sec-0015"> <h4 class="title">Types of interventions</h4> <p>Trials of oral azathioprine or 6‐mercaptopurine therapy were considered for inclusion.</p> </section> <section id="CD000545-sec-0016"> <h4 class="title">Types of outcome measures</h4> <p>The primary outcome was the proportion of patients with clinical remission as measured with a validated outcome (e.g. Crohn's Disease Activity Index score &lt; 150 points or a Harvey‐Bradshaw Index score &lt; 3). The proportion of patients with clinical improvement or remission was a secondary outcome. The definitions of remission and improvement varied from study to study making exact comparisons across studies difficult. Therefore, the definition of improvement or remission used in each study was used for data extraction. Other outcomes of interest included fistula improvement or healing, steroid sparing effect, adverse events, withdrawals due to adverse events, and serious adverse events. Included studies were also reviewed for adverse events commonly associated with antimetabolites including: leukopenia, infection, thrombocytopenia, malignancy, rash, fever, arthralgias, pancreatitis, hepatitis, nausea, non‐pancreatic abdominal pain, and diarrhea. </p> </section> </section> <section id="CD000545-sec-0017"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000545-sec-0018"> <h4 class="title">Electronic searches</h4> <p>We searched MEDLINE (Ovid), EMBASE (Ovid), and the Cochrane Library from inception to 30 October 2015. Conference proceedings were also searched to identify additional studies. The search strategy is reported in <a href="./appendices#CD000545-sec-0040">Appendix 1</a>. </p> </section> <section id="CD000545-sec-0019"> <h4 class="title">Searching other resources</h4> <p>We also searched conference proceedings and reference lists to identify additional studies. </p> </section> </section> <section id="CD000545-sec-0020"> <h3 class="title" id="CD000545-sec-0020">Data collection and analysis</h3> <section id="CD000545-sec-0021"> <h4 class="title">Study Selection:</h4> <p>Potentially relevant articles were reviewed in an independent unblinded fashion by two authors (CMT and CEP) to determine if they met the criteria specified above. For crossover studies, only data from the first portion of the study were incorporated to avoid possible carry‐over effects of medication into the second part of the study, and to make these studies more comparable to those not of a crossover design. All results were tabulated on an intention‐to‐treat basis. Reviewers rated each article as being eligible, ineligible, or not applicable to the current review. Any disagreement among reviewers was resolved by consensus. Trials published in abstract form only were not included unless full details of the protocol and results could be obtained from the authors. </p> </section> <section id="CD000545-sec-0022"> <h4 class="title">Data Collection:</h4> <p>Eligible articles were reviewed in duplicate and the results of the primary research trials were abstracted. Data were then extracted onto specially designed data extraction forms. </p> <p>We used the Cochrane risk of bias tool to assess the methodological quality of the included studies (<a href="./references#CD000545-bbs2-0057" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). The following study characteristics were assessed: </p> <p> <ol id="CD000545-list-0001"> <li> <p>Randomization sequence generation;</p> </li> <li> <p>Allocation concealment;</p> </li> <li> <p>Blinding of participants, outcome assessors and investigators;</p> </li> <li> <p>Incomplete outcome reporting (i.e. there was an acceptable method of dealing with attrition); </p> </li> <li> <p>Selective outcome reporting (i.e. all outcomes described in the methods were included in the analysis); and </p> </li> <li> <p>Other potential sources of bias.</p> </li> </ol> </p> <p>Based on these characteristics, studies were judged to have a high, low or unclear risk of bias. </p> <p>We used the GRADE approach to assess the overall quality of evidence for the primary outcome and selected secondary outcomes of interest. Outcomes from pooling of randomized trials start as high quality evidence, but may be downgraded due to: (1) risk of bias, (2) indirectness of evidence, (3) inconsistency (unexplained heterogeneity), (4) imprecision (sparse data), and (5) reporting bias (publication bias). The overall quality of evidence for each outcome was determined after considering each of these elements, and categorized as high quality (i.e. further research is very unlikely to change our confidence in the estimate of effect); moderate quality (i.e. further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate); low quality (i.e. further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate); or very low quality (i.e. we are very uncertain about the estimate) (<a href="./references#CD000545-bbs2-0053" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>; <a href="./references#CD000545-bbs2-0082" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). </p> </section> <section id="CD000545-sec-0023"> <h4 class="title">Statistical Analysis:</h4> <p>Data were analyzed using Review Manager (RevMan 5). The risk ratio (RR) and 95% confidence intervals (95% CI) were calculated for each dichotomous outcome. Data from individual trials were combined for meta‐analysis if the interventions, patient groups and outcomes were sufficiently similar (determined by consensus). A fixed‐effect model was used to pool data in the absence of heterogeneity. A random‐effects model was used when significant heterogeneity was detected. Heterogeneity was assessed using the Chi<sup>2</sup> test (a P value of 0.10 will be regarded as statistically significant). The l<sup>2</sup> statistic was used to estimate the degree of heterogeneity. This measure describes the percentage of total variation across studies that results from heterogeneity rather than chance. A value of 25% is considered to indicate low heterogeneity, 50% moderate heterogeneity and 75% high heterogeneity (<a href="./references#CD000545-bbs2-0056" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). Sensitivity analyses were used to explore potential sources of heterogeneity. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000545-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000545-sec-0024"></div> <section id="CD000545-sec-0025"> <h3 class="title">Description of studies</h3> <p>A literature search conducted on October 30, 2015 identified 1609 records. Seven additional studies were identified through searching of conference abstracts. After duplicates were removed, a total of 1161 trials remained for review of titles and abstracts. Two authors (CMT and CEP) independently reviewed the titles and abstracts of these trials and 59 studies were selected for full text review (see <a href="#CD000545-fig-0001">Figure 1</a>). Thirty‐two reports of 23 studies were excluded (See: <a href="./references#CD000545-sec-0051" title="">Characteristics of excluded studies</a>). Twenty‐seven reports of 13 trials met the pre‐defined inclusion criteria and were included in the review (<a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a>; <a href="./references#CD000545-bbs2-0002" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. ">Candy 1995</a>; <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>; <a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a>; <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>; <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>; <a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a>; <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>; <a href="./references#CD000545-bbs2-0013" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7731):944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). </p> <div class="figure" id="CD000545-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD000545-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>The 13 selected trials (n = 1211 patients) had a variety of designs: seven were exclusively concerned with therapy of active disease (<a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>; <a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>; <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>; <a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a>) and two trials had separate arms for patients with active and quiescent disease (<a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>; <a href="./references#CD000545-bbs2-0013" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7731):944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a> compared therapy with 6‐mercaptopurine, methotrexate, or placebo for active disease and subsequently for quiescent disease (if the patient responded) without randomizing for maintenance of remission therapy. In three trials patients were treated with 6‐mercaptopurine (<a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>). All the other included studies treated patients with azathioprine. Azathioprine is rapidly converted to 6‐mercaptopurine in vivo, and the clinical indications for using azathioprine and 6‐mercaptopurine are similar so it was decided that these trials could be pooled for meta‐analysis. The authors of the National Co‐operative Crohn's Disease Study (<a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>) divided their study into three parts and compared azathioprine, prednisone, sulfasalazine and placebo. Part I phase one dealt with patients with active disease, while part I phase two examined the ability of these patients to maintain their remission. Part II patients entered the study in remission. This review deals only with part I phase one for remission and all of part I for adverse event data (<a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>). <a href="./references#CD000545-bbs2-0002" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. ">Candy 1995</a> was divided into two parts. The first part treated active disease and the second part enrolled those who had successfully completed part one and examined their ability to maintain remission. This review deals only with part one of the Candy study. </p> <p>Six studies included active comparators (<a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a>; <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>; <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>). As described above, <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a> compared 6‐mercaptopurine to placebo or methotrexate; and <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a> examined azathioprine, prednisone, sulfasalazine and placebo. <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a> had three treatment arms including azathioprine, infliximab and infliximab plus azathioprine. Patients were followed for induction at 30 weeks and maintenance of remission at week 50 (<a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>). <a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a> compared treatment with infliximab to the combination of infliximab and azathioprine for active disease. Patients who were successfully induced at six weeks were entered into a one year maintenance phase and were treated with either infliximab or azathioprine alone (<a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a>). <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a> randomized patients to one of three treatments: 6‐mercaptopurine, azathioprine or 5‐aminosalicyclic acid. Patients were followed for induction of remission at 30 weeks and then for maintenance through 76 weeks. <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a> had three different treatment arms: everolimus, azathioprine and placebo. This trial was stopped early (at seven months) due to lack of efficacy of everolimus. </p> <p>All patients were symptomatic: some had an acute exacerbation of previously quiescent disease (<a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>), other patients had chronic disease unresponsive to other therapy such as steroids (<a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a>; <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000545-bbs2-0013" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7731):944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>), and some (<a href="./references#CD000545-bbs2-0002" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. ">Candy 1995</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>; <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>; <a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a>; <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>) were evaluated only on the severity of their symptoms at the time of randomization. The steroid sparing effect of therapy was a primary end point for some studies (<a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>; <a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>; <a href="./references#CD000545-bbs2-0013" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7731):944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>), while others (<a href="./references#CD000545-bbs2-0002" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. ">Candy 1995</a>; <a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a>) were concerned only with clinical response and did not consider the effect of concurrent medications. For some trials steroid free remission was the endpoint considered (<a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>). The National Cooperative Crohn's Disease Study (<a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>) measured only clinical response and by design excluded concurrent therapy. </p> <p>Remission was measured at various time points in the included studies. Remission was measured at 16 weeks in two studies (<a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>; <a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>). <a href="./references#CD000545-bbs2-0002" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. ">Candy 1995</a> and <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a> measured remission at 12 weeks. <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a> measured remission every month. <a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a> measured remission at six weeks. <a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a> and <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a> were cross‐over trials and the remission data before crossing over were used. <a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a> measured remission at two months and <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a> measured remission at one year. <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a> measured remission at 17 weeks. <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a> measured remission at 26 weeks. <a href="./references#CD000545-bbs2-0013" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7731):944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a> reported remission at 24 weeks. <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a> reported remission at 30 weeks. </p> </section> <section id="CD000545-sec-0026"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias for the included studies is summarized in <a href="#CD000545-fig-0002">Figure 2</a>. Overall the studies were of low risk of bias for most assessed items. All of the trials were described as randomized, however only four studies explained the method used for sequence generation (<a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a>; <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>; <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>). Four trials were rated as low risk of bias for allocation concealment (<a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>; <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>; <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>). The remaining studies did not explain methods used for allocation concealment and were rated as unclear for this item (<a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a>; <a href="./references#CD000545-bbs2-0002" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. ">Candy 1995</a>; <a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>; <a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a>; <a href="./references#CD000545-bbs2-0013" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7731):944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). Seven studies were rated as low risk for blinding (<a href="./references#CD000545-bbs2-0002" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. ">Candy 1995</a>; <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>; <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>; <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>; <a href="./references#CD000545-bbs2-0013" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7731):944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). <a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a> was single‐blind (investigator) and was rated as high risk for blinding. <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a> was rated as high risk of bias for blinding because it was open label. Blinding was not discussed in <a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a> and this study was rated as unclear for this study. Three studies were described as double‐blind but did not explain the methods used for blinding. These studies were rated as unclear for blinding (<a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a>). Nine studies were rated as low risk for incomplete outcome data (<a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a>; <a href="./references#CD000545-bbs2-0002" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. ">Candy 1995</a>; <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>; <a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a>; <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0013" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7731):944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). Four studies were rated as unclear for incomplete outcome data (<a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a>; <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>; <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>; <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>). Twelve studies reported all expected outcomes (<a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a>; <a href="./references#CD000545-bbs2-0013" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7731):944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>; <a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>; <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>; <a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>; <a href="./references#CD000545-bbs2-0002" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. ">Candy 1995</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a>; <a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a>; <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>; <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>). <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a> reported some additional <i>post hoc</i> analyses and was rated as unclear for selective reporting. No additional items of concern were noted and all studies were rated as low risk for other sources of bias (<a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a>; <a href="./references#CD000545-bbs2-0002" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. ">Candy 1995</a>; <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>; <a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a>; <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>; <a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a>; <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>; <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>; <a href="./references#CD000545-bbs2-0013" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7731):944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). </p> <div class="figure" id="CD000545-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000545-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD000545-sec-0027"> <h3 class="title" id="CD000545-sec-0027">Effects of interventions</h3> <p>See: <a href="./full#CD000545-tbl-0001"><b>Summary of findings for the main comparison</b> Azathioprine or 6‐mercaptopurine versus placebo for induction of remission in Crohn's disease</a>; <a href="./full#CD000545-tbl-0002"><b>Summary of findings 2</b> Azathioprine versus infliximab for induction of remission in Crohn's disease</a>; <a href="./full#CD000545-tbl-0003"><b>Summary of findings 3</b> Azathioprine + infliximab versus infliximab for induction of remission in Crohn's disease</a>; <a href="./full#CD000545-tbl-0004"><b>Summary of findings 4</b> Azathioprine or 6‐mercaptopurine versus methotrexate for induction of remission in Crohn's disease</a>; <a href="./full#CD000545-tbl-0005"><b>Summary of findings 5</b> Azathioprine or 6‐mercaptopurine versus 5‐ASA or Sulfasalzine for induction of remission in Crohn's disease</a> </p> <section id="CD000545-sec-0028"> <h4 class="title">Azathioprine or 6‐Mercaptopurine versus Placebo</h4> <p>Five placebo‐controlled studies ( <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Candy-1995" target="_blank">Candy 1995</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Ewe-1993" target="_blank">Ewe 1993</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Oren-1997" target="_blank">Oren 1997</a>;<a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Reinisch-2008" target="_blank">Reinisch 2008</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Summers-1979" target="_blank">Summers 1979</a>) involving 380 patients reported clinical remission at 12 to 17 weeks as an outcome using validated outcome measures (i.e. CDAI &lt; 150 or HBI &lt; 3). The pooled analysis showed that 48 per cent (95/197) of patients receiving antimetabolites achieved remission compared to 37% (68/183) of placebo patients (RR 1.23, 95% CI 0.97 to 1.55; <a href="./references#CD000545-fig-0003" title="">Analysis 1.1</a>). No statistically significant heterogeneity was detected for this comparison (P = 0.35; I<sup>2</sup> = 9%). A GRADE analysis indicated that the overall quality of the evidence for the primary outcome (clinical remission) was moderate due to sparse data (163 events, see <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#SOF-01" target="_blank">Summary of findings table 1</a>). Subgroup analysis showed no statistically significant difference in remission rates between azathioprine and placebo (4 studies, 322 patients) or 6‐mercaptopurine and placebo (1 study, 58 patients): P = 0.97; I<sup>2</sup> = 0%. Fifty‐two per cent (86/165) of azathioprine patients achieved remission compared to 40% (62/157) of placebo patients (RR 1.24, 95% CI 0.94 to 1.64). Twenty‐eight per cent (9/32) of 6‐mercaptopurine patients achieved remission compared to 23% (6/26) of placebo patients (RR 1.22, 95% CI 0.50 to 2.98). </p> <p>Nine placebo‐controlled studies (n = 506 patients) reported clinical remission or improvement as an outcome (<a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Candy-1995" target="_blank">Candy 1995</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Ewe-1993" target="_blank">Ewe 1993</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Klein-1974" target="_blank">Klein 1974</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Oren-1997" target="_blank">Oren 1997</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Present-1980" target="_blank">Present 1980</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Reinisch-2008" target="_blank">Reinisch 2008</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Rhodes-1971" target="_blank">Rhodes 1971</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Summers-1979" target="_blank">Summers 1979</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Willoughby-1971" target="_blank">Willoughby 1971</a>). The pooled analysis showed that 51 per cent (133/261) of patients receiving antimetabolites achieved clinical remission or improvement compared to 33% (80/245) of placebo patients (RR 1.53, 95% CI 1.05 to 2.22; <a href="./references#CD000545-fig-0004" title="">Analysis 1.2</a>). However, statistically significant heterogeneity was detected for this comparison (P = 0.006; I<sup>2</sup> = 64%). Subgroup analysis showed no statistically significant difference in remission or improvement rates between azathioprine and placebo (7 studies, 376 patients) or between 6‐mercaptopurine and placebo (2 studies, 130 patients): P = 0.36; I<sup>2</sup> = 0%. Fifty‐one per cent (98/193) of azathioprine patients achieved remission compared to 38% (69/183) of placebo patients (RR 1.28, 95% CI 0.96 to 1.71). No statistically significant heterogeneity was detected for the azathioprine subgroup comparison (P = 0.17; I<sup>2</sup> = 35%). Fifty‐one per cent (35/68) of 6‐mercaptopurine patients achieved remission compared to 18% (11/62) of placebo patients (RR 2.54, 95% CI 0.60 to 10.68). However, a large statistically significant amount of heterogeneity was detected for the 6‐mercaptopurine subgroup comparison (P = 0.02; I<sup>2</sup> = 82%). The heterogeneity appears to be a result of the inclusion of the <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Present-1980" target="_blank">Present 1980</a> study in the pooled analysis. The <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Present-1980" target="_blank">Present 1980</a> study was quite different than the other studies in the pooled analysis, as it did not use a validated outcome measure (e.g. CDAI) and it measured clinical improvement at one year whereas the other studies measured clinical remission or improvement between 6 and 28 weeks. To investigate if this study was the source of the heterogeneity the analysis was repeated excluding this trial. The pooled analysis now included 8 studies involving 434 patients. No statistically significant heterogeneity was detected for the overall comparison (P = 0.26; I<sup>2</sup> = 22%). Forty‐eight per cent (107/225) of patients receiving antimetabolites achieved clinical remission or improvement compared to 36% (75/209) of placebo patients (RR 1.26, 95% CI 0.98 to 1.62; <a href="./references#CD000545-fig-0005" title="">Analysis 1.3</a>). A GRADE analysis indicated that the quality of evidence was moderate due to sparse data (182 events, see <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#SOF-01" target="_blank">Summary of findings table 1</a>). </p> <p><a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Present-1980" target="_blank">Present 1980</a> reported that the mean time to response with 6‐mercaptopurine therapy in active Crohn's disease was 3.1 months, and that 19% of patients who responded took more than 16 weeks to respond.We therefore investigated the effect of duration of therapy on response (<a href="./references#CD000545-fig-0006" title="">Analysis 1.4</a>). When the active disease therapy data were analysed for the effect of duration of therapy (range 6 weeks to 12 months), the pooled risk ratio for response within 1 to 16 weeks was 1.08 (95% CI 0.83 to 1.40) and response with &gt; 17 weeks was 1.59 (95% CI 1.05 to 2.41). These risk ratios are not significantly different from one another as the confidence intervals overlap (P = 0.12; I<sup>2</sup> = 59%). Thus no conclusion can be drawn with respect to the length of therapy. </p> <p>Four placebo‐controlled studies reported fistula response as an outcome (<a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Klein-1974" target="_blank">Klein 1974</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Present-1980" target="_blank">Present 1980</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Rhodes-1971" target="_blank">Rhodes 1971</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Willoughby-1971" target="_blank">Willoughby 1971</a>;). Two trials (<a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Ewe-1993" target="_blank">Ewe 1993</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Summers-1979" target="_blank">Summers 1979</a>) reported no statistically significant difference in healing rates between placebo and therapy groups but did not include numerical data. <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Present-1980" target="_blank">Present 1980</a> reported the number of fistulae that responded rather than the number of patients with fistulae that responded, so their results could not be pooled for analysis. We defined fistula response as complete healing or decreased discharge. If a fistula developed during the study, it was included as "unhealed". The pooled analysis included 3 studies and 18 patients. Fifty‐four per cent (6/11) of azathioprine patients had a fistula response compared to 29% (2/7) of placebo patients (RR 2.00, 95% CI 0.67 to 5.93; <a href="./references#CD000545-fig-0007" title="">Analysis 1.5</a>). No statistically significant heterogeneity was detected for this comparison (P = 1.00, I<sup>2</sup> = 0%). A GRADE analysis indicated that the overall quality of the evidence for this outcome was low due to serious imprecision (very sparse data ‐ 8 events and wide confidence intervals). </p> <p>The ability to reduce prednisone or prednisolone dose was an important outcome measure for some studies. It was defined as the ability to follow a pre‐defined steroid tapering regimen, and the ability to reduce steroid dose to &lt; 10 mg/day while maintaining remission. Five studies reported the reduction of steroid consumption as an outcome (<a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Candy-1995" target="_blank">Candy 1995</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Ewe-1993" target="_blank">Ewe 1993</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Klein-1974" target="_blank">Klein 1974</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Present-1980" target="_blank">Present 1980</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Willoughby-1971" target="_blank">Willoughby 1971</a>). However, <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Present-1980" target="_blank">Present 1980</a> reported only cross‐over results for this outcome and we decided that it should not be included in the pooled analysis. The pooled analysis (4 studies, 143 patients) showed that sixty‐four per cent (47/73) of patients receiving azathioprine were able to reduce their prednisone dose to &lt; 10 mg/day compared to 46% (32/70) of placebo patients (RR 1.34, 95% CI 1.02 to 1.77; <a href="./references#CD000545-fig-0008" title="">Analysis 1.6</a>). No statistically significant heterogeneity was detected for this comparison (P = 0.40; I<sup>2</sup> = 0%). A GRADE analysis indicated that the overall quality of the evidence was moderate for this outcome due to sparse data. <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Present-1980" target="_blank">Present 1980</a> reported that during treatment with 6‐mercaptopurine in 44 patients, steroids could be discontinued in 23 patients and reduced in five (28/44). In 39 placebo patients steroids could be discontinued in five and reduced in one (6/39); RR 4.14, 95% CI 1.92 to 8.93. <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Oren-1997" target="_blank">Oren 1997</a> reported no statistically significant difference in steroid consumption or ability to taper steroids between 6‐mercaptopurine and placebo (data not shown). </p> <p>Commonly reported adverse events in the placebo‐controlled studies included allergic reactions (consisting of fever or rash or both and arthritis), leukopenia, pancreatitis and nausea. One study involving 80 patients reported the proportion of patients who experienced at least one adverse event (<a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>). Sixty‐nine per cent of patients in the azathioprine group experienced at least one adverse event compared to 86% of placebo patients (RR 0.81, 95% CI 0.64 to 1.02; <a href="./references#CD000545-fig-0009" title="">Analysis 1.7</a>). Eight placebo‐controlled trials reported the proportion of patients who withdrew due to adverse events (<a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Candy-1995" target="_blank">Candy 1995</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Ewe-1993" target="_blank">Ewe 1993</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Klein-1974" target="_blank">Klein 1974</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Present-1980" target="_blank">Present 1980</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Reinisch-2008" target="_blank">Reinisch 2008</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Rhodes-1971" target="_blank">Rhodes 1971</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Summers-1979" target="_blank">Summers 1979</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Willoughby-1971" target="_blank">Willoughby 1971</a>). The adverse events reported from <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Present-1980" target="_blank">Present 1980</a> include both arms of the cross‐over since data from the individual arms were not reported. All other data from cross‐over studies were reported from the period prior to cross‐over. The adverse events from <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Willoughby-1971" target="_blank">Willoughby 1971</a> include both an induction of remission for active disease arm and a maintenance of remission arm since data from the individual arms were not reported. <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Summers-1979" target="_blank">Summers 1979</a> reported adverse events from each part of the trial and did not split part I in to its phases. <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Oren-1997" target="_blank">Oren 1997</a> did not report adverse event data. The pooled analysis (8 studies, 510 patients) showed that ten per cent (28/266) of patients receiving antimetabolites withdrew due to adverse events compared to 5% (13/244) of placebo patients (RR 1.70, 95% CI 0.94 to 3.08; <a href="./references#CD000545-fig-0010" title="">Analysis 1.8</a>). No statistically significant heterogeneity was detected for this comparison (P = 0.68; I<sup>2</sup> = 0%). A GRADE analysis indicated that the overall quality of the evidence for this outcome was moderate due to sparse data (41 events, See <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#SOF-01" target="_blank">Summary of findings table 1</a>). Two studies (<a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Reinisch-2008" target="_blank">Reinisch 2008</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Summers-1979" target="_blank">Summers 1979</a>) including 216 patients reported the proportion of patients who experienced serious adverse events (<a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>; <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>). The pooled analysis showed that fourteen per cent (15/111) of patients in the antimetabolite group had a serious adverse event compared to 4% of placebo patients (RR 2.57, 95% CI 0.92 to 7.13; <a href="./references#CD000545-fig-0011" title="">Analysis 1.9</a>). There was no statistically significant heterogeneity detected for this analysis (P = 0.44; I<sup>2</sup> = 0%). A GRADE analysis indicated that the overall quality of the evidence for this outcome was low due to very sparse data (19 events) and very wide confidence intervals (See <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#SOF-01" target="_blank">Summary of findings table 1</a>). </p> </section> <section id="CD000545-sec-0029"> <h4 class="title">Azathioprine versus Infliximab</h4> <p><a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Colombel-2010" target="_blank">Colombel 2010</a> was the only study that compared azathioprine with infliximab. Clinical remission was a secondary outcome in this study. Patients with active Crohn's disease (CDAI 220 to 450) were included in the study. Clinical remission rates were higher in those randomized to receive infliximab compared to azathioprine. Thirty‐two per cent (54/170) of azathioprine patients achieved clinical remission at week 26 compared to 48% (81/169) of infliximab patients (339 patients, RR 0.66, 95% CI 0.51 to 0.87; <a href="./references#CD000545-fig-0012" title="">Analysis 2.1</a>). A GRADE analysis indicated that the quality of evidence was moderate due to sparse data (135 events, see <a href="./full#CD000545-tbl-0002">summary of findings Table 2</a>). Steroid free remission was the primary outcome in the <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Colombel-2010" target="_blank">Colombel 2010</a> study. More infliximab patients than azathioprine patients were able to achieve steroid free remission. Thirty per cent of azathioprine patients (51/170) achieved steroid free remission at 26 weeks compared to 44% (75/169) of infliximab patients (339 patients, RR 0.68, 95% CI 0.51 to 0.90; <a href="./references#CD000545-fig-0013" title="">Analysis 2.2</a>). A GRADE analysis indicated that the quality of evidence was moderate due to sparse data (126 events, see <a href="./full#CD000545-tbl-0002">summary of findings Table 2</a>). </p> <p><a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Colombel-2010" target="_blank">Colombel 2010</a> reported mucosal healing by colonoscopy as an outcome. Mucosal healing was defined as the absence of mucosal ulceration at week 26 in patients who had confirmed mucosal ulceration at baseline (<a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Colombel-2010" target="_blank">Colombel 2010</a>). Mucosal healing rates were higher in those randomized to receive infliximab compared to azathioprine. Twenty‐eight per cent (28/99) of infliximab patients had mucosal healing at week 26 compared to 16% (18/115) of azathioprine patients (RR 0.55, 95% CI 0.33 to 0.94; <a href="./references#CD000545-fig-0014" title="">Analysis 2.3</a>). A GRADE analysis indicated that the overall quality of evidence was moderate due to sparse data (46 events, see <a href="./full#CD000545-tbl-0002">summary of findings Table 2</a>). </p> <p><a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Colombel-2010" target="_blank">Colombel 2010</a> reported adverse events through week 54 of their trial. . Eighty‐nine per cent (144/161) of patients in the azathioprine group experienced at least one adverse event compared to 89% (145/163) of patients in the infliximab group (RR 1.01, 95% CI 0.93 to 1.08; <a href="./references#CD000545-fig-0015" title="">Analysis 2.4</a>). Common adverse events included nausea, abdominal pain, pyrexia and headache. Twenty‐six per cent (42/161) of azathioprine patients withdrew from the study because of an adverse event compared to 18% (29/163) of infliximab patients (RR 1.47, 95% CI 0.96 to 2.23; <a href="./references#CD000545-fig-0016" title="">Analysis 2.5</a>). Twenty‐seven per cent of azathioprine patients (43/161) experienced a serious adverse event compared to 24% (39/163) of infliximab patients (RR 1.12, 95% CI 0.77 to 1.62; <a href="./references#CD000545-fig-0017" title="">Analysis 2.6</a>). The overall quality of the evidence supporting these outcomes was moderate due to sparse data (see <a href="./full#CD000545-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD000545-sec-0030"> <h4 class="title">Azathioprine and Infliximab versus Infliximab</h4> <p>Two studies compared the combination of azathioprine and infliximab to infliximab alone (<a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a>). Only <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a> reported the outcome of clinical remission. Sixty per cent (102/169) of patients in the combination therapy group achieved clinical remission compared to 48% (81/169) of infliximab patients (338 patients, RR 1.26, 95% CI 1.03 to 1.54; <a href="./references#CD000545-fig-0018" title="">Analysis 3.1</a>). A GRADE analysis indicates that the overall quality of the evidence for this outcome was moderate due to sparse data (183 events, See <a href="./full#CD000545-tbl-0003">summary of findings Table 3</a>). Both studies (<a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a>) reported steroid‐free clinical remission as an outcome. Sixty per cent (116/194) of patients in the combination therapy group achieved steroid‐free clinical remission compared to 48% (91/189) of infliximab patients (383 patients, RR 1.23, 95% CI 1.02 to 1.47; <a href="./references#CD000545-fig-0019" title="">Analysis 3.2</a>). A GRADE analysis indicates that the overall quality of the evidence for this outcome was moderate due to sparse data (207 events, See <a href="./full#CD000545-tbl-0003">summary of findings Table 3</a>). <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a> reported mucosal healing. After 26 weeks of therapy, 42% (47/111) of patients in the combination therapy group achieved mucosal healing compared to 28% (28/99) of patients in the infliximab group (RR 1.50, 95% CI 1.02 to 2.19; <a href="./references#CD000545-fig-0020" title="">Analysis 3.3</a>). A GRADE analysis indicates that the overall quality of the evidence for this outcome was moderate due to sparse data (75 events, see <a href="./full#CD000545-tbl-0003">summary of findings Table 3</a>). </p> <p><a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a> reported that ninety per cent (161/179) of patients in the combination therapy group experienced an adverse event compared to 89% (145/163) of infliximab patients (RR 1.01, 95% CI 0.94 to 1.09; <a href="./references#CD000545-fig-0021" title="">Analysis 3.4</a>). A GRADE analysis indicates that the overall quality of the evidence for this outcome was moderate due to sparse data (306 events, see <a href="./full#CD000545-tbl-0003">summary of findings Table 3</a>). Twenty‐one per cent (37/179) of patients in the combination therapy group withdrew due to adverse events compared to 18% (29/163) of infliximab patients (RR 1.16, 95% CI 0.75 to 1.80; <a href="./references#CD000545-fig-0022" title="">Analysis 3.5</a>). A GRADE analysis indicates that the overall quality of the evidence for this outcome was moderate due to sparse data (66 events, see <a href="./full#CD000545-tbl-0003">summary of findings Table 3</a>). Fifteen per cent of patients in the combination therapy group (27/179) experienced a serious adverse event compared to 24% (39/163) of infliximab patients (RR 0.63, 95% CI 0.41 to 0.98; <a href="./references#CD000545-fig-0023" title="">Analysis 3.6</a>). A GRADE analysis indicates that the overall quality of the evidence for this outcome was moderate due to sparse data (66 events, see <a href="./full#CD000545-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD000545-sec-0031"> <h4 class="title">Azathioprine or 6‐Mercaptopurine versus Methotrexate</h4> <p>Two studies compared 6‐MP to methotrexate (<a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; ). <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a> used the Harvey‐Bradshaw Index to evaluate disease activity. Those with a score of ≥ 7 were included in the study and remission was defined as a Harvey‐Bradshaw score of ≤ 3 and no steroid use. <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a> included patients with steroid dependent Crohn's disease, defined as the inability to taper steroids below 20 mg/day without presenting symptoms of active disease (e.g. CDAI &gt; 200). Remission was defined as CDAI &lt; 150 with normal orosomucoid serum concentrations after discontinuing steroids. <a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a> compared azathioprine to methotrexate. <a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a> enrolled patients with active Crohn's disease (CDAI ≥ 200) with the need for steroids. <a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a> defined remission as CDAI ≤ 150 and the discontinuation of steroid treatment. A pooled analysis (3 studies, n = 143 patients) revealed that 60% (45/75) of patients in the antimetabolites group achieved steroid‐free remission compared to 57% (39/68) of methotrexate patients (RR 1.13, 95% CI 0.85 to 1.49; <a href="./references#CD000545-fig-0024" title="">Analysis 4.1</a>). No statistically significant heterogeneity was detected for this comparison (P = 0.95; I<sup>2</sup> = 0%). A GRADE analysis indicates that the overall quality of the evidence for this outcome was low due to sparse data (75 events) and a high risk of bias in two of the studies in the pooled analysis (See <a href="./full#CD000545-tbl-0004">summary of findings Table 4</a>). </p> <p>These studies provided little data on adverse events. <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a> did not report adverse event data. <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a> pooled adverse event data for Crohn's disease and ulcerative colitis, therefore only some of the adverse events were interpretable for Crohn's disease. <a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a> provided adequate information with respect to adverse events. A pooled analysis (2 studies, 85 patients) showed that adverse events were more likely in patients receiving methotrexate compared to azathioprine or 6‐MP. Overall, adverse events occurred in 19% (8/43) of azathioprine or 6‐MP patients compared to 45% (19/42) of methotrexate patients (RR 0.42, 95% CI 0.21 to 0.82; <a href="./references#CD000545-fig-0025" title="">Analysis 4.2</a>). A GRADE analysis indicates that the overall quality of the evidence for this outcome was low due to sparse data (27 events) and a high risk of bias in two of the studies in the pooled analysis. Adverse events leading to withdrawal occurred in 9% (4/43) of azathioprine or 6‐MP patients compared to 12% (5/42) of methotrexate patients (RR 0.78, 95% CI 0.23 to 2.71; <a href="./references#CD000545-fig-0026" title="">Analysis 4.3</a>). A GRADE analysis indicates that the overall quality of the evidence for this outcome was very low due to sparse data (9 events), very wide confidence intervals and a high risk of bias in two of the studies in the pooled analysis. No serious adverse events were reported in these studies. </p> </section> <section id="CD000545-sec-0032"> <h4 class="title">Azathioprine or 6‐Mercaptopurine versus 5‐Aminosalicyclic Acid or Sulfasalazine</h4> <p><a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a> compared 6‐MP to 5‐ASA. <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a> compared azathioprine to sulfasalazine. A pooled analysis of two studies (n = 156) revealed that forty‐eight per cent (36/75) of patients in the antimetabolite group achieved remission compared to 36% (29/81) of patients who received 5‐ASA or sulfasalazine (RR 1.24, 95% CI 0.80 to 1.91; <a href="./references#CD000545-fig-0027" title="">Analysis 5.1</a>). There was statistically significant heterogeneity detected for this analysis (P = 0.03; I<sup>2</sup> = 79%). A GRADE analysis indicates that the overall quality of the evidence for this outcome was very low due to sparse data (65 events), a high risk of bias in the <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a> study, and unexplained heterogeneity (See <a href="./full#CD000545-tbl-0005">summary of findings Table 5</a>). Nine per cent of 6‐MP patients (7/75) withdrew due to adverse events compared to 10% of patients (8/81) in the aminosalicylates group (156 patients, RR 0.98, 95% CI 0.38 to 2.54; <a href="./references#CD000545-fig-0028" title="">Analysis 5.2</a>). There was no statistically significant heterogeneity detected for this comparison (P = 0.81; I<sup>2</sup> = 0%). A GRADE analysis indicates that the overall quality of the evidence for this outcome was low due to sparse data (15 events) and a high risk of bias in the <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a> study. <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a> did not report serious adverse events and neither of the studies reported the proportion of patients who experienced at least one adverse event (<a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>;). <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a> reported serious adverse events as an outcome. Seven per cent of patients in the 6‐MP group experienced a serious adverse event compared to 0% of 5‐ASA patients (RR 11.25, 95% CI 0.62 to 204.86; <a href="./references#CD000545-fig-0029" title="">Analysis 5.3</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000545-sec-0033" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000545-sec-0033"></div> <p>This updated review includes 13 randomized controlled trials (n = 1211 patients) which examined the efficacy of azathioprine or 6‐mercaptopurine for inducing remission in Crohn's disease. These trials compared these antimetabolites to placebo and various active therapies including infliximab, methotrexate and 5‐aminosalicylate. The definitions of remission and improvement varied from study to study making exact comparisons across studies difficult. Only 5 of 9 (<a href="./references#CD000545-bbs2-0002" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. ">Candy 1995</a>; <a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Summers-1979" target="_blank">Summers 1979</a>) placebo‐controlled studies used generally accepted and validated criteria (either a Crohn's Disease Activity Index score &lt; 150 points or a Harvey‐Bradshaw Index score &lt; 3 points) to define remission. The other four studies used subjective improvement or other non‐validated outcome measures (<a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Rhodes-1971" target="_blank">Rhodes 1971</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1212051447563223872046645433900%26format=REVMAN#STD-Willoughby-1971" target="_blank">Willoughby 1971</a>). Azathioprine or 6‐mercaptopurine therapy was possibly modestly better than placebo (5 studies, 380 patients, RR 1.23, 95% CI 0.97 to 1.55, moderate certainty evidence) for achieving clinical remission. When clinical remission or improvement is considered as an outcome, azathioprine or 6‐mercaptopurine therapy was possibly better than placebo (434 patients, RR 1.26, 95% CI 0.98 to 1.62, moderate certainty evidence). These results suggest that azathioprine and 6‐mercaptopurine possibly offer a modest advantage over placebo for induction of remission or clinical improvement in active Crohn's disease. We believe that the methodological basis for these conclusions is sound. The quality of the individual trials was assessed using the Cochrane risk of bias tool and the possibility of bias was judged to be low for these studies. A GRADE analysis indicated that the overall quality of the evidence supporting these outcomes is moderate due to sparse data, hence we cannot have complete certainty in the estimates. These findings agree with a recent meta‐analysis of immunosuppressives in inflammatory bowel disease (<a href="./references#CD000545-bbs2-0060" title="KhanK , DubinkskyM , FordA , UllmanT , TalleyN , MoayyediP . Efficacy of immunosuppressive therapy for inflammatory bowel Disease: A systematic review and meta‐analysis. American Journal of Gastroenterology2011;106:630‐42. ">Khan 2011</a>). </p> <p>The ability to taper or discontinue corticosteroids is an important outcome to consider when treating Crohn's disease. Four older trials (<a href="./references#CD000545-bbs2-0002" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. ">Candy 1995</a>; <a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>; <a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000545-bbs2-0013" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7731):944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>) reported steroid‐sparing (e.g. final prednisone dose &lt; 10 mg/day) as an outcome. A pooled analysis of these studies showed that azathioprine was possibly effective compared to placebo (143 patients, RR 1.34, 95% CI 1.02 to 1.77). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was moderate. The role of combined antimetabolite and steroid therapy in active disease has been controversial. The National Cooperative Crohn's Disease Study (<a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>) failed to show a statistically significant benefit for azathioprine monotherapy and has been criticised for not allowing concurrent steroid therapy during the lag period before azathioprine could act, and for not allowing sufficient time to assess the response to azathioprine (<a href="./references#CD000545-bbs2-0061" title="KorelitzBI , PresentDH . Shortcomings of the National Crohn's Disease Study: the exclusion of azathioprine without adequate trial. Gastroenterology1981;80(1):193‐6. ">Korelitz 1981</a>). Combination therapy with azathioprine and steroids may lead to a higher response rate with less steroid use. </p> <p>More recent trials comparing antimetabolites to other active therapies reported steroid‐free clinical remission as an outcome (<a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a>; <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a>; <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000545-bbs2-0010" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103(9):2284‐92. ">Reinisch 2008</a>). The evidence is very uncertain about the effectiveness of 6‐Mercaptopurine in inducing steroid‐free remission compared to 5‐aminosalicyclates (23 patients, RR 6.56, 95% CI 1.06 to 40.46). This uncertainty is due to the small number of patients included in the analysis and the poor methodological quality of the <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a> study. The overall quality of the evidence was rated as very low using the GRADE approach due to this risk of bias, imprecision and inconsistency. The <a href="./references#CD000545-bbs2-0008" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a> study is not adequate to determine the relative benefits of 6‐mercaptopurine versus methotrexate. The sample size was small, both drugs were probably under‐dosed (6‐mercaptopurine 50 mg/day and methotrexate 12.5 mg/week orally), and neither drug was reported to be superior to placebo. A trial comparing oral 6‐mercaptopurine 1.5 mg/kg/d or azathioprine 2 to 3 mg/kg/d with parenteral methotrexate 25 mg/wk for chronic active Crohn's disease would be of interest. A pooled analysis including three studies found a difference in steroid‐free clinical remission between azathioprine or 6‐mercaptopurine and methotrexate (143 patients, RR 1.13, 95% CI 0.85 to 1.49). However, the results of this pooled analysis need to be interpreted with caution due to the small number of patients included in the analysis and because of a high risk of bias in two of the studies in the pooled analysis ( <a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a>; <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>). Furthermore, none of the three studies in the pooled analysis were designed as formal non‐inferiority studies. A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low. Azathioprine and 6‐mercaptopurine may be better choices as first line steroid sparing agents than methotrexate due to the propensity for adverse effects. A pooled analysis of two studies found that patients taking methotrexate may be more likely than patients taking azathioprine or 6‐mercaptopurine to experience an adverse event (85 patients, RR 0.42, 95% CI 0.21 to 0.82; low quality evidence). More high quality trials comparing azathioprine or 6‐mercaptopurine with 5‐aminosalicyclates or methotrexate are required to determine the true comparative efficacy and safety of these interventions. </p> <p>Azathioprine was found to be probably less effective than infliximab (339 patients, RR 0.66, 95% CI 0.51 to 0.87) for achieving clinical remission. The addition of azathioprine to infliximab probably improved clinical remission rates (338 patients, RR 1.26, 95% CI 1.03 to 1.54) compared to azathioprine alone. The combination of azathioprine and infliximab was found to be probably superior to infliximab alone (383 patients, RR 1.23, 95% CI1.02 to 1.47) for induction of steroid‐free remission. Azathioprine was found to be probably inferior to infliximab therapy (339 patients, RR 0.68, 95% CI 0.51 to 0.90) for induction of steroid‐free remission. The reason for the uncertainty in these estimate is our GRADE analysis which rated the overall quality of the evidence for these comparison as moderate. <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a> also reported mucosal healing as an outcome. Azathioprine was found to be probably inferior to infliximab for mucosal healing (RR 0.55, 95% CI 0.33 to 0.94). The combination of azathioprine and infliximab was found to be probably superior to infliximab alone for mucosal healing (RR 1.50, 95% CI 1.02 to 2.19). Again, the reason for the uncertainty is that our GRADE analysis rated the overall quality of the evidence for these outcomes as moderate due to sparse data. More high quality trials comparing the combination of azathioprine with infliximab to infliximab alone are required to confirm the benefit of this combination. </p> <p>The use of azathioprine for refractory fistulae was originally based on uncontrolled reports (<a href="./references#CD000545-bbs2-0038" title="Avery‐JonesF , Lennard‐JonesJE , HintonJM , ReevesWG . Dangers of immuno‐suppressive drugs in ulcerative colitis (letter). British Medical Journal1966;1:1418. ">Avery‐Jones 1966</a>; <a href="./references#CD000545-bbs2-0043" title="BrownCH , AchkarE . Azathioprine therapy for inflammatory bowel disease. A preliminary report. American Journal of Gastroenterology1970;54(4):363‐77. ">Brown 1970</a>; <a href="./references#CD000545-bbs2-0041" title="BrookeBN , JavettSL , DavisonOW . Further experience with azathioprine for Crohn's disease. Lancet1970;2(7682):1050‐3. ">Brooke 1970</a>; <a href="./references#CD000545-bbs2-0049" title="DruckerWR , JeejeebhoyKN . Azathioprine: an adjunct to surgical therapy of granulomatous enteritis. Annals of Surgery1970;172(4):618‐26. ">Drucker 1970</a>; <a href="./references#CD000545-bbs2-0062" title="KorelitzBI , PresentDH . Favorable effect of 6‐mercaptopurine on fistulae of Crohn's disease. Digestive Diseases and Sciences1985;30(1):58‐64. ">Korelitz 1985</a>). For three placebo controlled trials that reported numerical results ( <a href="./references#CD000545-bbs2-0005" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a>; <a href="./references#CD000545-bbs2-0013" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7731):944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>;), azathioprine therapy was found to have a possible advantage over placebo for fistula healing (RR 2.00, 95% CI 0.67 to 5.93). However, this pooled analysis included only 18 patients and further research is necessary to determine if azathioprine provides a benefit for fistula healing. In the <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a> study, forty fistulae were observed in 36 patients, and 9/29 (31%) of fistulae closed completely during treatment with 6‐mercaptopurine compared with 1/17 (6%) of fistulae which closed during treatment with placebo (these numbers represent overlapping patients, some who crossed over and some who did not). The <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a> data were not included in this systematic review because the data were reported as the number of fistulae closing, rather than the number of patients who had complete fistulae closure, and because the fistulae data were not presented in a way that made separation of the results from the first phase of the crossover study possible. The principal author of this study was contacted, and the original data are no longer available to address these issues. The results from two other studies which reported no significant effect ( <a href="./references#CD000545-bbs2-0004" title="EweK , PressAG , SingeCC , StuflerM , UeberschaerB , HommelG , et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology1993;105(2):367‐72. EweK , PressAG , SingeCC , StuflerM , UeberschaerB , Meyer zum BuschenfeldeKH , et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology1992;102(4 Part 2):A 621. ">Ewe 1993</a>; <a href="./references#CD000545-bbs2-0012" title="MekhjianHS , SwitzDM , MelnykCS , RankinGB , BrooksRK . Clinical features and natural history of Crohn's disease. Gastroenterology1979;77(4 Pt 2):898‐906. SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology1979;77(4 Pt 2):870‐82. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Pt 2):847‐69. WinshipDH , SummersRW , SingletonJW , BestWR , BecktelJM , LenkLF , et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology1979;77(4 Pt 2):829‐42. ">Summers 1979</a>) also could not be included in the analysis because the fistulae data were not available. The lack of specific reporting on fistula response in these two trials may represent publication bias, as negative results were not reported. A randomized, double‐blind, placebo‐controlled trial of azathioprine designed to specifically address the question of efficacy in the subgroup of patients with fistulizing (perforating) Crohn's disease would be of interest. </p> <p>The adverse effects of antimetabolite therapy are well recognised ( <a href="./references#CD000545-bbs2-0037" title="AlsteadEM , RitchieJK , Lennard‐JonesJE , FarthingMJ , ClarkML . Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology1990;99(2):443‐6. ">Alstead 1990</a>; <a href="./references#CD000545-bbs2-0054" title="HaberCJ , MeltzerSJ , PresentDH , KorelitzBI . Nature and course of pancreatitis caused by 6‐mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology1986;91(4):982‐6. ">Haber 1986</a><a href="./references#CD000545-bbs2-0011" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a>; <a href="./references#CD000545-bbs2-0077" title="RosmanM , BertinoJR . Azathioprine. Annals of Internal Medicine1973;79(5):694‐700. ">Rosman 1973</a>). Patients with Crohn's disease may have similar symptoms, so a comparison with a control group is useful to estimate the incidence of adverse effects attributable to therapy. Patients receiving azathioprine or 6‐mercaptopurine may be more likely to withdraw due to an adverse event. <a href="./references#CD000545-bbs2-0076" title="PresentDH , MeltzerSJ , KrumholzMP , WolkeA , KorelitzBI . 6‐Mercaptopurine in the management of inflammatory bowel disease: short‐ and long‐term toxicity. Annals of Internal Medicine1989;111(8):641‐9. ">Present 1989</a> reviewed their extensive experience with 6‐mercaptopurine in 396 patients with inflammatory bowel disease and approximately 1800 patient‐years of follow‐up. <a href="./references#CD000545-bbs2-0076" title="PresentDH , MeltzerSJ , KrumholzMP , WolkeA , KorelitzBI . 6‐Mercaptopurine in the management of inflammatory bowel disease: short‐ and long‐term toxicity. Annals of Internal Medicine1989;111(8):641‐9. ">Present 1989</a> reported a higher incidence of adverse reactions, presumably due to the longer duration of therapy and observation: significant infection (7.4%), pancreatitis (3.3%), neoplasm (3.1%), bone marrow suppression (2.0%), allergy (2.0%), and drug‐induced hepatitis (0.3%). <a href="./references#CD000545-bbs2-0072" title="O'BrienJJ , BaylessTM , BaylessJA . Use of azathioprine or 6‐mercaptopurine in the treatment of Crohn's disease. Gastroenterology1991;101(1):39‐46. ">O'Brien 1991</a> reported an overall 10% incidence of adverse events sufficiently severe to justify stopping azathioprine or 6‐mercaptopurine in their uncontrolled series of 78 patients with Crohn's disease. Two studies detailing the low toxicity of azathioprine with respect to bone marrow suppression and cancer risk in 755 patients with inflammatory bowel disease treated over 27 years have been reported (<a href="./references#CD000545-bbs2-0045" title="ConnellWR , KammMA , RitchieJK , Lennard‐JonesJE . Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut1993;34(8):1081‐5. ">Connell 1993</a>; <a href="./references#CD000545-bbs2-0046" title="ConnellWR , KammMA , DicksonM , BalkwillAM , RitchieJK , Lennard‐JonesJE . Long‐term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet1994;343(8908):1249‐52. ">Connell 1994</a>). A follow‐up report of patients with Crohn's disease treated with azathioprine or 6‐mercaptopurine for up to 166 months did not show an increase in toxicity with long term use (<a href="./references#CD000545-bbs2-0039" title="BouhnikY , LemannM , MaryJY , ScemamaG , TaiR , MatuchanskyC , et al. Long‐term follow‐up of patients with Crohn's disease treated with azathioprine or 6‐mercaptopurine. Lancet1996;347(8996):215‐9. ">Bouhnik 1996</a>). More recent studies confirm the low risk of bone marrow suppression and cancer in IBD patients treated with azathioprine (<a href="./references#CD000545-bbs2-0051" title="FraserAG , OrchardTR , RobinsonEM , JewellDP . Long‐term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Alimentary Pharmacology and Therapeutics2002;16(7):1225‐32. ">Fraser 2002</a>; <a href="./references#CD000545-bbs2-0052" title="GisbertJP , GomollónF . Thiopurine‐induced myelotoxicity in patients with inflammatory bowel disease: a review. American Journal of Gastroenterology2008;103(7):1783‐800. ">Gisbert 2008</a>). The time course for the occurrence of adverse events is variable. Allergic reactions and pancreatitis usually occur within a few weeks of beginning therapy, whereas bone marrow suppression, infection, and hepatitis may occur at any time. It was not possible to ascertain from the controlled trials reviewed for this meta‐analysis what the time course was for the various forms of drug toxicity observed. </p> <p>Four active comparator trials reported the proportion of patients who experienced at least one adverse event (<a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a>; <a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>; <a href="./references#CD000545-bbs2-0006" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A54. ">Mantzaris 2004</a>; <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>). The difference in adverse events rates between azathioprine and infliximab was probably neglible (RR 1.01, 95% CI 0.93 to 1.08). Furthermore, the combination of azathioprine and infliximab was found to probably have a similar rate of adverse events compared to infliximab alone (RR 1.01, 95% CI 0.94 to 1.09). Data on withdrawals due to adverse events were available for all of the comparisons. The differences in withdrawals secondary to adverse events between the various drugs were as follows: azathioprine or 6‐mercaptopurine and methotrexate: RR 0.78, 95% CI 0.23 to 2.71; 6‐mercaptopurine and aminosalicylates: RR 0.98, 95% CI 0.38 to 2.54 and azathioprine and infliximab: RR 1.47, 95% CI 0.96 to 2.23. The risk ratio for combined therapy with infliximab and azathioprine compared to infliximab alone was 1.16, 95% CI 0.75 to 1.80. The rate of serious adverse events was only reported in one study (<a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>). Azathioprine was found to probably have a similar serious adverse event rate compared to infliximab (RR 1.12, 95% CI 0.77 to 1.62). However, the addition of azathioprine to infliximab was found to probably decrease the risk of a serious adverse event compared to infliximab alone (RR 0.63, 95% CI 0.41 to 0.98). The reason for uncertainty is that GRADE analyses indicated that the overall quality of the evidence supporting these outcomes was low to moderate due to sparse data (<a href="./references#CD000545-bbs2-0003" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Supplementary Appendix. New England Journal of Medicine2010;362. ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics2015;41(8):734‐46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week2008. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:S13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the Sonic study: A randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136(5 Suppl 1):A116. ">Colombel 2010</a>) or high risk of bias (<a href="./references#CD000545-bbs2-0001" title="ArdizzoneS , BollaniS , ManzionnaG , ImbesiV , ColomboE , Bianchi PorroG . Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease2003;35(9):619‐27. ArdizzoneS , BollaniS , ManzionnaG , MolteniP , Bianchi PorroG . Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology1999;116(4):A662‐3. ">Ardizzone 2003</a>; <a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a>). Further research is necessary to assess the long term safety of azathioprine and 6‐mercaptopurine. </p> <p>The above findings from the present meta‐analysis highlight some of the problems with the use of azathioprine or 6‐mercaptopurine in active Crohn's disease. First and foremost, our meta‐analysis shows that antimetabolite therapy possibly provides a modest benefit over placebo for induction of remission or clinical improvement in active Crohn's disease, but the evidence is of moderate quality due to the imprecision of the effect estimate. </p> <p>Antimetabolite therapy may take a few months before onset of drug action (e.g. approximately three months, <a href="./references#CD000545-bbs2-0009" title="PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. PresentDH , WischN , GlassJL , KorelitzBI . The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology1977;72(5ii):A‐91. ">Present 1980</a>; <a href="./references#CD000545-bbs2-0078" title="SahasranamanS , HowardD , RoyS . Clinical pharmacology and pharmacogenetics of thiopurines. European Journal of Clinical Pharmacology2008;64:753‐67. ">Sahasranaman 2008</a>). To explore this we analyzed placebo‐controlled trials by the time point when remission or clinical improvement was measured. Azathioprine or 6‐mercaptopurine patients evaluated at 17 weeks or later were probably more likely to be in remission than those taking placebo (RR 1.59, 95% CI 1.05 to 2.41). When remission or clinical improvement was measured before 17 weeks there was probably a smaller difference between antimetabolites and placebo (RR 1.08, 95% CI 0.83 to 1.40). These results suggest that a period of 17 weeks may be the minimum time period for an adequate trial of antimetabolite therapy. It had been postulated that the apparent long duration of therapy required to achieve benefit may be due to a requirement for equilibration of the active metabolite of the drug within tissues. It was also suggested that a high intravenous loading dose of the drug might overcome this problem (<a href="./references#CD000545-bbs2-0079" title="SandbornWJ , VanOsEC , ZinsBJ , TremaineWJ , MaysDC , LipskyJJ . An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology1995;109(6):1808‐17. ">Sandborn 1995</a>). However, a placebo‐controlled trial of intravenous azathioprine loading (40 mg/kg over 36 hours) in patients with active steroid‐refractory Crohn's disease receiving oral azathioprine did not show any benefit (<a href="./references#CD000545-bbs2-0081" title="SandbornWJ , TremaineWJ , WolfDC , TarganSR , SninskyCA , SutherlandLR , et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid‐treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology1999;117(3):527‐35. ">Sandborn 1999</a>). </p> <p>Apart from potentially expediting induction of steroid‐free remission, azathioprine may have a role as an adjunctive therapy to infliximab. This was illustrated by the likely superiority of the combination of infliximab and azathioprine to monotherapy with azathioprine or infliximab. Therapy with azathioprine and 6‐mercaptopurine may help to prevent the development of antibodies to infliximab. The development of antibodies to infliximab has been associated with a loss of response to infliximab and the development of infusion reactions. An analysis of the ACCENT I data by Hanauer and colleagues found that patients who received immunosuppressive therapy (i.e. azathioprine, 6‐mercaptopurine or methotrexate) in conjunction with infliximab had a significantly lower chance of developing antibodies to infliximab than patients who received infliximab monotherapy (<a href="./references#CD000545-bbs2-0055" title="HanauerSB , WagnerCL , BalaM , MayerL , TraversS , DiamondRH , et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clinical Gastroenterology and Hepatology2004;2(7):542‐53. ">Hanauer 2004</a>). However, patients who were found to be positive for these antibodies were not less likely to have a clinical response or be in clinical remission at the end of the study. These results should be interpreted with caution as only 80 patients had positive antibodies (<a href="./references#CD000545-bbs2-0055" title="HanauerSB , WagnerCL , BalaM , MayerL , TraversS , DiamondRH , et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clinical Gastroenterology and Hepatology2004;2(7):542‐53. ">Hanauer 2004</a>). Future trials should evaluate the interaction between antimetabolite therapy and infliximab with respect to antibody formation and efficacy. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD000545-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD000545-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000545-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 1 Clinical remission." data-id="CD000545-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 1 Clinical remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 2 Clinical remission or improvement." data-id="CD000545-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 2 Clinical remission or improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 3 Clinical remission or improvement (sensitivity analysis)." data-id="CD000545-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 3 Clinical remission or improvement (sensitivity analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 4 Clinical remission or improvement by trial duration." data-id="CD000545-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 4 Clinical remission or improvement by trial duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 5 Fistula improvement or healing." data-id="CD000545-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 5 Fistula improvement or healing. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 6 Steroid sparing effect (final prednisone dose &lt; 10 mg/day)." data-id="CD000545-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 6 Steroid sparing effect (final prednisone dose &lt; 10 mg/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 7 Adverse events." data-id="CD000545-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 7 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 8 Withdrawals due to adverse events." data-id="CD000545-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 8 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 9 Serious adverse events." data-id="CD000545-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐Mercaptopruine versus placebo, Outcome 9 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine versus Infliximab, Outcome 1 Clinical remission through 26 weeks." data-id="CD000545-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine versus Infliximab, Outcome 1 Clinical remission through 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine versus Infliximab, Outcome 2 Steroid‐free remission through 26 weeks." data-id="CD000545-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine versus Infliximab, Outcome 2 Steroid‐free remission through 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine versus Infliximab, Outcome 3 Mucosal healing through 26 weeks." data-id="CD000545-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine versus Infliximab, Outcome 3 Mucosal healing through 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine versus Infliximab, Outcome 4 Adverse events." data-id="CD000545-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine versus Infliximab, Outcome 4 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine versus Infliximab, Outcome 5 Withdrawals due to adverse events." data-id="CD000545-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine versus Infliximab, Outcome 5 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine versus Infliximab, Outcome 6 Serious adverse events through 54 weeks." data-id="CD000545-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine versus Infliximab, Outcome 6 Serious adverse events through 54 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 1 Clinical remission." data-id="CD000545-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 1 Clinical remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 2 Steroid‐free clinical remission." data-id="CD000545-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 2 Steroid‐free clinical remission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 3 Mucosal healing through 26 weeks." data-id="CD000545-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 3 Mucosal healing through 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 4 Adverse events." data-id="CD000545-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 4 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 5 Withdrawals due to adverse events." data-id="CD000545-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 5 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 6 Serious adverse events." data-id="CD000545-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 6 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Azathioprine or 6‐Mercaptopurine versus Methotrexate, Outcome 1 Steroid‐free remission." data-id="CD000545-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Azathioprine or 6‐Mercaptopurine versus Methotrexate, Outcome 1 Steroid‐free remission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Azathioprine or 6‐Mercaptopurine versus Methotrexate, Outcome 2 Adverse events." data-id="CD000545-fig-0025" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Azathioprine or 6‐Mercaptopurine versus Methotrexate, Outcome 2 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Azathioprine or 6‐Mercaptopurine versus Methotrexate, Outcome 3 Withdrawals due to adverse events." data-id="CD000545-fig-0026" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Azathioprine or 6‐Mercaptopurine versus Methotrexate, Outcome 3 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Azathioprine or 6‐Mercaptopurine versus 5‐Aminosalicylic acid or Sulfasalazine, Outcome 1 Steroid‐free clinical remission." data-id="CD000545-fig-0027" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Azathioprine or 6‐Mercaptopurine versus 5‐Aminosalicylic acid or Sulfasalazine, Outcome 1 Steroid‐free clinical remission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Azathioprine or 6‐Mercaptopurine versus 5‐Aminosalicylic acid or Sulfasalazine, Outcome 2 Withdrawals due to adverse events." data-id="CD000545-fig-0028" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Azathioprine or 6‐Mercaptopurine versus 5‐Aminosalicylic acid or Sulfasalazine, Outcome 2 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000545-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/urn:x-wiley:14651858:media:CD000545:CD000545-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_t/tCD000545-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Azathioprine or 6‐Mercaptopurine versus 5‐Aminosalicylic acid or Sulfasalazine, Outcome 3 Serious adverse events." data-id="CD000545-fig-0029" src="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Azathioprine or 6‐Mercaptopurine versus 5‐Aminosalicylic acid or Sulfasalazine, Outcome 3 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/media/CDSR/CD000545/image_n/nCD000545-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000545-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus placebo for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Azathioprine (AZA) or 6‐mercaptopurine (6‐MP) versus placebo for induction of remission in Crohn's disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with active Crohn's disease<br/> <b>Settings:</b> Outpatients<br/> <b>Intervention:</b> Azathioprine or 6‐mercaptopurine versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>AZA or 6‐MP versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>372 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b><br/> (361 to 577) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> <br/> (0.97 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>380<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical remission or improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>359 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>452 per 1000</b><br/> (352 to 582) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.26</b> <br/> (0.98 to 1.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>434<br/> (8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fistula improvement or healing</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>286 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>572 per 1000</b><br/> (192 to 1696) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.00</b> <br/> (0.67 to 5.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Steroid sparing effect</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>457 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>612 per 1000</b><br/> (466 to 809) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.34</b> <br/> (1.02 to 1.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>53 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>90 per 1000</b><br/> (50 to 163) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.70</b> </p> <p>(0.94 to 3.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>510<br/> (8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>38 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>98 per 1000</b> </p> <p>(35 to 271)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.57</b> </p> <p>(0.92 to 7.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>216 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of meta‐analysis, based on included trials<br/> <sup>2</sup> Sparse data (163 events)<br/> <sup>3</sup> Sparse data (182 events)<br/> <sup>4</sup> Sparse data (8 events) and very wide confidence intervals<br/> <sup>5</sup> Sparse data (79 events)<br/> <sup>6</sup> Sparse data (41 events) </p> <p><sup>7</sup> Sparse data (19 events) and very wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus placebo for induction of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000545-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azathioprine versus infliximab for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Azathioprine (AZA) versus infliximab (IFX) for induction of remission in Crohn's disease</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with active Crohn's disease<br/> <b>Settings:</b> Outpatients<br/> <b>Intervention:</b> Azathioprine versus infliximab </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>AZA versus IFX</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>479 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b><br/> (244 to 417) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.66</b> <br/> (0.51 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>339<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical remission off steroids</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>444 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>302 per 1000</b><br/> (226 to 400) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.68</b> <br/> (0.51 to 0.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>339<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mucosal healing</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>283 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>156 per 1000</b><br/> (93 to 266) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.55</b> <br/> (0.33 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>214<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>890 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>899 per 1000</b><br/> (828 to 961) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b> <br/> (0.93 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>178 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>262 per 1000</b><br/> (171 to 397) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.47</b> <br/> (0.96 to 2.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>239 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>268 per 1000</b><br/> (184 to 387) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.12</b> <br/> (0.77 to 1.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of the study<br/> <sup>2</sup> Sparse data (135 events)<br/> <sup>3</sup> Sparse data (126 events)<br/> <sup>4</sup> Sparse data (46 events)<br/> <sup>5</sup> Sparse data (289 events)<br/> <sup>6</sup> Sparse data (71 events)<br/> <sup>7</sup> Sparse data (82 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azathioprine versus infliximab for induction of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000545-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azathioprine + infliximab versus infliximab for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Azathioprine (AZA) + infliximab (IFX) versus infliximab for induction of remission in Crohn's disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with active Crohn's disease<br/> <b>Settings:</b> Outpatients<br/> <b>Intervention:</b> Azathioprine + infliximab versus infliximab </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>AZA + IFX versus IFX</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>479 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>603 per 1000</b><br/> (493 to 738) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> <br/> (1.03 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical remission off steroids</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>482 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>593 per 1000</b><br/> (492 to 708) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.23</b> <br/> (1.02 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mucosal healing</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>283 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>424 per 1000</b><br/> (289 to 620) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.50</b> <br/> (1.02 to 2.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>890 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>899 per 1000</b><br/> (837 to 970) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b> <br/> (0.94 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>178 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>206 per 1000</b><br/> (134 to 320) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.16</b> <br/> (0.75 to 1.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>239 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>151 per 1000</b><br/> (98 to 234) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.63</b> <br/> (0.41 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of the study<br/> <sup>2</sup> Sparse data (183 events)<br/> <sup>3</sup> Sparse data (207 events)<br/> <sup>4</sup> Sparse data (75 events)<br/> <sup>5</sup> Sparse data (306 events)<br/> <sup>6</sup> Sparse data (66 events)<br/> <sup>7</sup> Sparse data (66 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azathioprine + infliximab versus infliximab for induction of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000545-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus methotrexate for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Azathioprine (AZA) or 6‐mercaptopurine (6‐MP) versus methotrexate (MTX) for induction of remission in Crohn's disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with active Crohn's disease<br/> <b>Settings:</b> Outpatients<br/> <b>Intervention:</b> Azathioprine or 6‐mercaptopurine versus methotrexate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>AZA or 6‐MP versus MTX</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>565 per 1000</b><br/> (425 to 1210) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> <br/> (0.85 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>452 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>190 per 1000</b><br/> (95 to 371) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.42</b> <br/> (0.21 to 0.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>5,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>119 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>93 per 1000</b><br/> (27 to 322) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.78</b> <br/> (0.23 to 2.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very</b> l<b>ow</b><sup>7,8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Definition of clinical remission includes withdrawal from steroids.<br/> <sup>2</sup> Control group risk estimates come from control arm of meta‐analysis, based on included trials<br/> <sup>3</sup> Sparse data (75 events)<br/> <sup>4</sup> Two of the studies in the pooled analysis were rated as having a high risk of bias due to single‐blind and open label designs<br/> <sup>5</sup> Sparse data (27 events)<br/> <sup>6</sup> The two studies in the pooled analysis were rated as having a high risk of bias due to single‐blind and open label designs<br/> <sup>7</sup> Sparse data (9 events) and very wide confidence intervals<br/> <sup>8</sup> The two studies in the pooled analysis were rated as having a high risk of bias due to single‐blind and open label designs </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus methotrexate for induction of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000545-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus 5‐ASA or Sulfasalzine for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>6‐mercaptopurine (6‐MP) versus 5‐ASA for induction of remission in Crohn's disease</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with active Crohn's disease<br/> <b>Settings:</b> Outpatients<br/> <b>Intervention:</b> Azathioprine or 6‐mercaptopurine versus 5‐ASA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6‐MP versus 5‐ASA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>358 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>444 per 1000</b><br/> (286 to 684) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.24</b> (0.80 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>99 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>97 per 1000</b> (38 to 251) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.98</b> (0.38 to 2.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>3,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of study<br/> <sup>2</sup> Sparse data (65 events)<br/> <sup>3</sup><a href="./references#CD000545-bbs2-0007" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero‐PeronaJ , Moreno‐OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12(11):1227‐33. ">Maté‐Jiménez 2000</a> was rated as having a high risk of bias due to open label design </p> <p><sup>4</sup> Unexplained heterogeneity </p> <p><sup>5</sup> Sparse data (15 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus 5‐ASA or Sulfasalzine for induction of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/full#CD000545-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000545-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Azathioprine or 6‐Mercaptopruine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.97, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.94, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 6‐Mercaptopurine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.50, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical remission or improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.05, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.96, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 6‐Mercaptopurine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [0.60, 10.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical remission or improvement (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.98, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.96, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 6‐Mercaptopurine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.50, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical remission or improvement by trial duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.98, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 trials ≥17 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.05, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 trials &lt;17 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.83, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fistula improvement or healing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.67, 5.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Steroid sparing effect (final prednisone dose &lt; 10 mg/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.02, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.64, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.94, 3.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.92, 7.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Azathioprine or 6‐Mercaptopruine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000545-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Azathioprine versus Infliximab</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical remission through 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.51, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Steroid‐free remission through 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.51, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mucosal healing through 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.33, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.93, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.96, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious adverse events through 54 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.77, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Azathioprine versus Infliximab</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000545-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Azathioprine and Infliximab versus Infliximab</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.03, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Steroid‐free clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.02, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mucosal healing through 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.02, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.75, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.41, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Azathioprine and Infliximab versus Infliximab</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000545-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Azathioprine or 6‐Mercaptopurine versus Methotrexate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Steroid‐free remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.85, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.21, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.23, 2.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Azathioprine or 6‐Mercaptopurine versus Methotrexate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000545-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Azathioprine or 6‐Mercaptopurine versus 5‐Aminosalicylic acid or Sulfasalazine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Steroid‐free clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.80, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.38, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.25 [0.62, 204.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Azathioprine or 6‐Mercaptopurine versus 5‐Aminosalicylic acid or Sulfasalazine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000545.pub5/references#CD000545-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000545.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000545-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000545-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD000545-note-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD000545-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD000545-note-0007">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000545\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000545\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000545\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000545\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000545\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000545.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000545.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000545.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000545.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000545.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714129991"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000545.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714129995"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000545.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6727ad88937d',t:'MTc0MDcxNDEzMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 